IgA Nephropathy Mechanisms and Management

IgA nephropathy is the most prevalent primary glomerulonephritis worldwide, characterised by deposition of immunoglobulin A (IgA), predominantly the IgA1 subclass, within the renal mesangium. A central mechanistic framework involves aberrant O-glycosylation of the hinge region of IgA1 molecules, yielding galactose-deficient IgA1 (Gd-IgA1) that acts as an autoantigen. Circulating anti-glycan antibodies bind Gd-IgA1 to form immune complexes which deposit in glomerular mesangial regions, triggering local complement activation—principally via the alternative and lectin pathways—and provoking mesangial proliferation, extracellular matrix expansion and proinflammatory cytokine release. Genetic predispositions at multiple susceptibility loci modulate both IgA glycosylation and complement regulation, contributing to geographic and ethnic variation in disease prevalence. Clinically, presentation ranges from isolated haematuria to progressive proteinuria and declining estimated glomerular filtration rate (eGFR). Management comprises optimisation of blood pressure and proteinuria control through renin–angiotensin–aldosterone system inhibitors and sodium-glucose co-transporter-2 (SGLT2) inhibitors, together with judicious use of corticosteroids or targeted immunosuppressants in high-risk patients. Emerging strategies include selective complement blockade and non-invasive biomarker panels for early diagnosis and risk stratification. Ongoing research seeks to refine molecular diagnostics, tailor therapies to pathogenic pathways and improve long-term renal survival.

Research from Nature Portfolio

Genome-wide analysis in a large Han Chinese cohort has identified new susceptibility loci that influence expression of key glycosylation enzymes and immune regulators. Variants at genes encoding the principal glycosyltransferase C1GALT1 and its molecular chaperone C1GALT1C1 modulate circulating levels of Gd-IgA1, revealing a direct genetic influence on the first hit of the multi-hit pathogenic model. Additional risk alleles correlate with mRNA expression in blood cells and mirror geographical gradients in disease incidence. Functional studies confirm that altered transcription of these loci drives secretion of aberrantly glycosylated IgA1, providing a genomic basis for targeted disruption of autoantigen formation.

IgA Nephropathy Mechanisms and Management publication trend

The graph below shows the total number of articles in iga nephropathy mechanisms and management across all publications each year (not limited to Nature Index journals).

Technical terms

Galactose-deficient IgA1 (Gd-IgA1): IgA1 molecules lacking galactose residues on hinge-region O-glycans, acting as autoantigens.

Mesangium: Central region of the glomerular tuft where immune complexes deposit and provoke injury.

Estimated glomerular filtration rate (eGFR): Clinical measure of kidney function based on serum creatinine.

Renin–angiotensin–aldosterone system inhibitors (RAASi): Drugs that lower blood pressure and reduce proteinuria by blocking angiotensin II effects.

Sodium-glucose co-transporter-2 (SGLT2) inhibitor: Class of antihyperglycaemic agents that improve renal outcomes by reducing glomerular hyperfiltration and albuminuria.

Complement pathways: Cascades (alternative, lectin, classical) of proteolytic activation leading to inflammation and cell injury.

References

1. Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLOS Genetics (2012).
2. The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Frontiers in Immunology (2016).
3. Identification of new susceptibility loci for IgA nephropathy in Han Chinese. Nature Communications (2015).
4. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International (2021).
5. A Panel of Serum Biomarkers Differentiates IgA Nephropathy from Other Renal Diseases. PLOS ONE (2014).
6. Circulating complement factor H–related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney International (2017).
7. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Frontiers in Immunology (2019).